More on STOK

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-41.5% Growth)
- Ratings (8.2 Score)

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Stoke Therapeutics Inc. (NQ:STOK)
Delayed: 29.34 -0.58 (1.94%)
Prev. Close $29.92  
Open$29.62 
52 Wk High$ 
52 Wk Low$ 
Day High$29.79 
Day Low$28.96 
P/E N/A  
EPS$ 
Volume421,296 

Friends, Peers and Foes (?): BIIB, VRTX, ZEAL, ANVS, ARQT (more...)

Sep 10, 2026 04:57 AM Goldman Sachs Reiterates Buy Rating on Stoke Therapeutics (STOK) Post Investor Meeting
Sep 4, 2026 06:00 AM Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
Sep 3, 2026 07:30 PM Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
Sep 1, 2026 07:30 AM Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
Sep 1, 2026 07:30 AM Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
Aug 21, 2026 03:28 AM JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight
Aug 18, 2026 08:30 PM Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry
Aug 18, 2026 08:29 PM Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD
Aug 18, 2026 08:27 PM Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan
Aug 18, 2026 04:01 PM Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
View All Articles

Entities mentioned with STOK

View All Entities